| Accession |
PRJCA016223 |
| Title |
Phase II clinical study of PD-1 antibody SHR-1210 combined with apatinib mesylate in the treatment of advanced non-small cell lung cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the tolerability and safety of PD-1 antibody SHR-1210 combined with apatinib mesylate in the treatment of patients with advanced non-small cell lung cancer (NSCLC) |
| Sample scope |
Multiisolate |
| Release date |
2023-04-13 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-13 |
